On Wednesday, ValueTheMarkets’ Ben Turney hosted Maurice Treacy, director at rare disease and orphan drug-focused pharma services company Open Orphan, in a recorded presentation and interview.
Treacy began by providing shareholders and potential investors with a detailed run through his firm’s robust range of services including its Virtual Rep database and its Genomic Health Data platform. He then went on to cover the opportunity on offer in Europe’s fast-growing orphan drug market and Open Orphan’s plans to consolidated the region’s fragmented pharma services sector through acquisitions.
Following an initial presentation, Treacy took a number of audience questions. These spanned a number of interesting topics such as the background of Open Orphan’s board, the company’s competition, its growth strategy, and the potential for a re-rate in its valuation.
For a full recording of the presentation, please see below:
